Telemedicine Extends Brigham’s Rich History of Neurosurgical Innovation to Underserved Areas

Woman wearing mask sitting on couch holding up tablet with female doctor on telemedicine video call

Advances in telemedicine are enabling the Brigham to bring high-quality neurosurgical care to patients nationally and internationally. Timothy R. Smith, MD, PhD, MPH, of the Department of Neurosurgery, discusses how these efforts reflect the broader movement to meet patients’ right to healthcare globally.


Could an Intranasal Vaccine Transform Alzheimer’s Prevention and Treatment?

Diagram of Alzheimer's disease with amyloid plaques, neurofilbrillary tangles, and neuronal loss

A groundbreaking intranasal vaccine for Alzheimer’s disease (AD) developed at Brigham shows tremendous promise in its first phase of human trials. Study leader Howard L. Weiner, MD, discusses the trial’s progress to date, planned future phases, and how the vaccine could shape the future of AD care.


Progressive Parental Leave Policy in the Mass General Brigham Neurology Residency

Father holds up infant, mother watching while smiling

Mass General Brigham Neurology Residency leaders recently revised its parental leave policy to better embody equity, fairness, transparency, and wellness values. They discuss the impact of the updated policy and offer suggestions for other programs that wish to implement a parental leave policy with similar goals.


Glioblastoma: Creating a Viral Oasis in an Immune Desert

Dana-Farber Brigham Cancer Center is world-renowned for its commitment to cutting-edge research. Over the years, its researchers have turned scientific discoveries into life-saving treatments, contributing to the development of 35 of 75 cancer drugs recently approved by the FDA for use in cancer patients. Read More

New Tool Allows Early Prediction of Disease Course in Multiple Sclerosis

Rendering of orange microglia cells damaging the myelin sheath of neuron axons

Using machine learning, researchers in the Brigham Multiple Sclerosis Center and colleagues have developed a tool for predicting what the outcome of patients with recently diagnosed MS will be in 10 years.


Adults With TBI May Benefit From Screening for Cardiometabolic Disease, Other Comorbidities

Female doctor shows brain scan images to older male patient in hospital bed

An analysis of prospectively collected data has demonstrated that adults who sustain traumatic brain injury (TBI), regardless of age and injury severity, are at higher risk of certain cardiovascular, endocrine, neurologic, and psychiatric disorders.


Review: Targeting Oncometabolism to Maximize Immunotherapy in Brain Cancer

Cells stained with different colors in a false color image of a tumour sample

Joshua D. Bernstock, MD, PhD, in the Department of Neurosurgery at Brigham and Women’s Hospital, Gregory K. Friedman, MD, of the University of Alabama at Birmingham, and colleagues reviewed novel therapies that target oncometabolism and tumor immunometabolism.


Traumatic Brain Injury: a Chronic Disease That Affects More Than the Brain

Scientists and clinicians are starting to recognize links between traumatic brain injury and comorbidities such as cardiometabolic disease. Brigham associate neurologist Saef Izzy, MD, MBChB, discusses what he has observed in studying these links as well as possible implications for clinical care.


Menopausal Hormone Therapy Linked to Increased Risk of Pituitary Adenoma

Woman sitting down holding a pack of menopausal hormone therapy pills

David J. Cote, MD, PhD, and Meir J. Stampfer, MD, DrPH, of the Channing Division of Network Medicine at Brigham and Women’s Hospital, and colleagues have conducted the first prospective study of associations between pituitary adenoma and the use of oral contraceptives or menopausal hormone therapy.


“Off-the-Shelf” Engineered Stem Cell Therapy for Glioblastoma Prolongs Survival in Animal Model

Glioblastoma brain cancer cells under microscope

Researchers at Brigham and Women’s Hospital have designed a biologic agent, dubbed EnMSCBif, to bind to death receptor 5 (DR5) on the surface of glioblastoma cells and trigger extrinsic programmed cell death. They report on the high potential of EnMSCBif to be translated into clinical use.